You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大藥廠(00950.HK)簽訂授權許可協議及出售附屬股權
阿思達克 10-05 10:07
李氏大藥廠(00950.HK)公布,全資附屬Lee’s International及間接全資附屬兆科廣州作為被授權人,與外商獨資企業及Zhaoke Ophthalmology訂立授權許可協議。根據協議,授權人同意向被授權人授出有關授權產品於授權地區的獨家許可權,作為代價,被授權人同意根據授權許可協議的條款向授權人支付預付金1,000萬美元,將以股份購回方式或現金支付,另有里程金500萬美元及銷售佣金。

公司表示,股份購回將構成Lee’s International出售Zhaoke Ophthalmology股權的出售事項。假設兆科A系列優先股獲全數轉換,公司透過Lee’s International於Zhaoke Ophthalmology的間接權益為50.117%,而Zhaoke Ophthalmology為公司的間接非全資附屬公司。

於股份購回完成後,公司於Zhaoke Ophthalmology的間接權益將由約50.117%下降至48.539%,Zhaoke Ophthalmology將不再為公司的間接非全資附屬公司,而兆科集團的財務業績亦不會於公司的綜合財務報表中綜合入賬。公司估計,出售事項將錄得1.86億元收益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account